Endo, Penwest to block Actavis plan for Opana ingredient

02/18/2008 | American City Business Journals

Endo Pharmaceuticals Holdings and Penwest Pharmaceuticals Co. have declared they will "pursue all available legal and regulatory avenues" to defend patents for their Opana ER pain drug after Actavis South Atlantic said it is seeking FDA approval for extended-release tablets with Opana's active ingredient. Endo and Penwest say Opana is protected until June 22, 2009.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA